Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Neuropsychological Profile and Cognitive Trajectories of Patients With Biomarker Evidence of Alzheimer Disease or Dementia With Lewy bodies.

Neurology·2026
Same author

Landscape of copy number variants in Spanish people with dementia.

NPJ genomic medicine·2026
Same author

Practice effects as a dynamic biomarker of early cognitive change in far-from-onset Huntington's disease.

Brain communications·2026
Same author

Improving the clinical trial landscape for patients with atypical variants of Alzheimer's disease: a call to action.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Atrophy signature for alpha-synuclein copathology in Alzheimer's disease.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Synucleinopathy-like clinical features and biologically defined synuclein seeding in PSP-Parkinsonism: an imperfect match.

NPJ Parkinson's disease·2026

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Miquel Massons1, Jordi Sarto2, Núria Guillén2

  • 1Alzheimer's disease and other cognitive disorders Unit. Hospital Clínic de Barcelona. Fundació de Recerca Clínic Barcelona - IDIBAPS. University of Barcelona, Barcelona, Spain.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括
此摘要是机器生成的。

血pTau217是诊断阿尔茨海默病 (AD) 的高精度生物标志物,为目前的方法提供了不那么侵入性的替代方案. 这项研究支持其在临床实践中用于改善诊断统一性的使用.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经科学是一个神经科学.
  • 生物标志物发现发现
  • 临床诊断 临床诊断 临床诊断

背景情况:

  • 阿尔茨海默病 (AD) 是导致痴呆的主要原因,需要改进诊断工具.
  • 化陶 (pTau217) 和神经纤维光链 (NF-L) 等等离子体生物标志物显示出作为CSF和PET扫描的替代品的希望.
  • 这项多中心研究旨在评估血pTau217和NF-L在AD中的诊断效用.

研究的目的:

  • 为了评估血pTau217和NF-L的诊断准确性,与已确立的AD的CSF生物标志物相比.
  • 探索这些血生物标志物的潜力,以广泛的临床实施和诊断标准化.
  • 分析人口因素对血生物标志物水平的影响.

主要方法:

  • 在加泰罗尼亚七家医院招募轻度认知障碍或痴呆症患者.
  • 使用Lumiplex G.使用pTau217和NF-L水平的血测量.
  • 将诊断准确度与CSF生物标志物进行比较,并分析人口统计学影响 (年龄,性别,BMI,GFR).

主要成果:

  • 血pTau217在检测粉样蛋白病理 (Aβ+) 方面表现出高精度,使用特定的切断值,灵敏度高达95%,特异性高达95%.
  • 在神经退行性疾病中,NF-L水平升高,但诊断精度低 (AUC=0.634).
  • 像BMI和GFR这样的人口因素对生物标志物水平和诊断性能的影响很小.

结论:

  • 血pTau217是一种高度准确的AD诊断生物标志物,可能减少对CSF或PET的需求.
  • 对于pTau217的两个诊断值是最佳的,中间范围可能表明早期的AD.
  • 虽然NF-L表明神经退行,但它在本研究中的临床实用性是有限的;pTau217支持更广泛的临床采用.